MYGN Myriad Genetics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why MYGN matters now
Myriad Genetics, Inc. (MYGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.10 with +3.92% on the session and $576.1M in market capitalization; recent performance reads 1-month +27.89% and YTD -26.18%.
The latest financial table shown here is Q1 2026, with revenue of $200.4M, net income of $-34.1M, and EPS of $-0.36. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.9%.
The latest indexable market news headline is "New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $6.00; recent insider activity includes Donnelly Brian J filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.26
P/S
0.52
EV/EBITDA
-1.54
DCF Value
$-19.56
FCF Yield
-4.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.0%
Operating Margin
-46.3%
Net Margin
-48.2%
ROE
-109.1%
ROA
-59.4%
ROIC
-69.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $200.4M | $-34.1M | $-0.36 |
| Q4 2025 | $209.8M | $-7.9M | $-0.08 |
| FY 2025 | $824.5M | $-365.9M | $-3.96 |
| Q3 2025 | $205.7M | $-27.4M | $-0.29 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.64
Myriad Genetics, Inc. is a leading company specializing in genetic testing and precision medicine. The firm focuses on developing and marketing a wide array of genetic diagnostic solutions across both domestic U.S. and international landscapes. Their extensive diagnostic offerings cater to crucial medical fields, including oncology, women's health, and mental well-being. In cancer diagnostics, Myriad provides several sophisticated molecular tests. These include the MyRisk Hereditary Cancer Test, which uses DNA sequencing to evaluate an individual's susceptibility to inherited cancer types. The BRACAnalysis CDx functions as a vital companion diagnostic, leveraging DNA sequencing to inform treatment strategies for patients with metastatic breast, ovarian, pancreatic, or prostate cancers carrying specific deleterious BRCA gene variants. Another key oncology product, the MyChoice CDx, is a tumor-based assay designed to ascertain homologous recombination deficiency status in ovarian cancer patients. Myriad also offers prognostic tools like the Prolaris Prostate Cancer Prognostic Test and the EndoPredict Breast Cancer Prognostic Test, both employing RNA expression analysis to gauge the aggressiveness of prostate and breast cancers, respectively. Furthermore, they offer Precise Tumor, a comprehensive solution aimed at guiding personalized cancer treatment. For women's health and prenatal care, Myriad presents essential screening options. The Prequel Prenatal Screen is a non-invasive maternal blood test used to identify significant chromosomal abnormalities in a fetus. Prospective parents can also utilize the Foresight Carrier Screen to assess their risk of transmitting recessive genetic conditions to their children. Addressing mental health, Myriad offers the GeneSight Psychotropic Mental Health Medication Test. This DNA genotyping test assists healthcare providers in optimizing the selection of psychotropic medications for individuals suffering from conditions such as depression, anxiety, and ADHD. Myriad Genetics has also established strategic alliances, notably with Illumina, Inc. and Intermountain Precision Genomics, to enhance its provision of both germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.